Hayley Virgil

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

The investigational drug CFI-402257 alone and in combination with fulvestrant received fast track designation from the FDA for patients with estrogen receptor–positive, HER2-negative advanced breast cancer.

Azeliragon was first evaluated in a group of patients with Alzheimer’s disease prior to being assessed in patients with glioblastoma, a fast-growing and aggressive brain tumor.

Adding the investigational oral drug BXCL701 to pembrolizumab appears effective in small cell neuroendocrine metastatic castration-resistant prostate cancer, a rare and aggressive disease.

A contingent of patients with a type of lung cancer and breast cancer continues to experience responses to treatment with zotatifin, according to updated study findings.

A stool-based, non-invasive, at-home colorectal cancer and advanced adenoma test showed a strong ability to detect disease, according to updated trial results.

The overall survival improvements were observed when tumor-treating fields were combined with immune checkpoint inhibitors with a positive trend towards improvement when combined with docetaxel in those with stage IV non–small cell lung cancer.

Japanese patients with relapsed/refractory large B-cell lymphoma can now receive treatment with axicabtagene ciloleucel following its approval.

The FDA’s decision means that oncologists can use FoundationOne Liquid CDx to identify patients with ROS1-positive non–small cell lung cancer or NTRK fusion–positive solid tumors who are eligible for treatment with entrectinib.

Bringing clinical cancer research to the community setting could offer better accessibility and lower costs without sacrificing quality of care.

The blood test is intended for use in detecting a range of cancers—including liver and lung cancer—among adults ages 50 to 75 years.

The decision to approve durvalumab plus tremelimumab in Japan for patients with advanced non–small cell lung cancer and unresectable biliary tract cancer and liver cancer was based on data from several phase 3 studies.

Durvalumab plus tremelimumab has been recommended for approval in the European Union for treatment of advanced liver and lung cancers.

Data presented at this year’s American Society of Hematology Annual Meeting spotlight promising novel treatment options for acute myeloid leukemia, according to an expert from The University of Texas MD Anderson Cancer Center.

Patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in the European Union can now receive treatment with fam-trastuzumab deruxtecan-nxki following its approval.

Fam-trastuzumab deruxtecan-nxki has been recommended for approval by the European Union’s Committee for Medicinal Products for Human Use in patients with HER2-low advanced breast cancer.

The original guidance was published as a draft 2 years ago, detailing the FDA's thoughts on the development of agents for the treatment of acute myeloid leukemia.

The FDA has now requested that the manufacturer of melphalan flufenamide withdraw the multiple myeloma drug from the United States market months after the drug developer rescinded a letter voluntarily withdrawing the therapeutic.

Patients in China diagnosed with high-risk neuroblastoma can now receive treatment with naxitamab-gqgk, which was recently given the greenlight by the National Medical Products Administration.

177Lu vipivotide tetraxetan becomes first targeted radioligand treatment approved by the European Commission for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Patients with high-risk Bacillus Calmette Guérin–unresponsive non-muscle invasive bladder cancer can now receive treatment with nadofaragene firadenovec-vncg—the first gene therapy—following its approval by the FDA.

The new drug application for avasopasem for radiotherapy-induced severe oral mucositis in patients with head and neck cancer is supported by findings from the phase 3 ROMAN trial and phase 2b GT-201 trial.

The FDA has received a biologic license application for talquetamab to treat relapsed/refractory multiple myeloma.

The use of two separate recommended phase 2 doses of talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma, according to updated trial findings presented at 2022 American Society of Hematology Annual Meeting.

Adults and children with unresectable or metastatic alveolar soft part sarcoma—one of the rarest types of sarcoma—can now receive treatment with atezolizumab, which was given the nod of approval by the FDA.

Treatment with a range of camizestrant monotherapy doses resulted in a survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

The FDA has followed the recommendation of its Oncologic Drugs Advisory Committee and issued a complete response letter denying approval to 131I-omburtamab as a treatment for central nervous system and leptomeningeal metastases stemming from neuroblastoma.

The multi-kinase inhibitor AUM302 received orphan drug designation from FDA for the treatment of neuroblastoma.

Patients with newly diagnosed prostate cancer benefitted from 18F-rHPSMA-7.3 PET when used prior to surgery.

Patients with cisplatin-ineligible muscle-invasive bladder cancer experienced a better rate of downstaging and improved survival benefit with neoadjuvant pembrolizumab prior to radical cystectomy vs immediate radical cystectomy.